Advanced search
Publication Cover
Renal Failure Volume 27, 2005 - Issue 4
Submit an article Journal homepage
615
Views
39
CrossRef citations to date
0
Altmetric
Clinical Study

Effect of Sevelamer on Dyslipidemia and Chronic Inflammation in Maintenance Hemodialysis Patients

Kazuhiro Yamada First Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Miyazaki, JapanCorrespondence[email protected]
, M.D.,
Shouichi Fujimoto First Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Miyazaki, Japan
, M.D.,
Takeshi Tokura Chiyoda Hospital, Miyazaki, Japan
, M.D.,
Keiichi Fukudome Miyazaki Syakaihoken Hospital, Miyazaki, Japan
, M.D.,
Hideyuki Ochiai Miyazaki Junkanki Hospital, Miyazaki, Japan
, M.D.,
Hiroyuki Komatsu First Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Miyazaki, Japan
, M.D.,
Yuji Sato First Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Miyazaki, Japan
, M.D.,
Seiichiro Hara First Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Miyazaki, Japan
, M.D. &
Tanenao Eto First Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Miyazaki, Japan
, M.D. show all
Pages 361-365 | Published online: 07 Jul 2009

References

  • Longenecker, J C.; Coresh, J.; Powe, N R.; Levey, A S.; Fink, N E.; Martin, A.; Klag, M J. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J. Am. Soc. Nephrol. 2002, 13 (7), 1918–1927. [PUBMED], [INFOTRIEVE], [CSA]
  • Bleyer, A J.; Burke, S K.; Dillon, M.; Garrett, B.; Kant, K S.; Lynch, D.; Rahman, S N.; Schoenfeld, P.; Teitelbaum, I.; Zeig, S.; Slatopolsky, E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. 1999, 33 (4), 694–701. [PUBMED], [INFOTRIEVE]
  • Chertow, G M.; Burke, S K.; Dillon, M A.; Slatopolsky, E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol. Dial. Transplant. 1999, 14 (12), 2907–2914. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • McIntyre, C W.; Patel, V.; Taylor, G S.; Fluck, R J. A prospective study of combination therapy for hyperphosphatemia with calcium-containing phosphate binders and sevelamer in hypercalcemic hemodialysis patients. Nephrol. Dial. Transplant. 2002, 17 (9), 1643–1648. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Pedersen, T R.; Wilhelmsen, L.; Faergeman, O.; Strandberg, T E.; Thorgeirsson, G.; Troedsson, L.; Kristianson, J.; Berg, K.; Cook, T J.; Haghfelt, T.; Kjekshus, J.; Miettinen, T.; Olsson, A G.; Pyorala, K.; Wedel, H. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am. J. Cardiol. 2000, 86 (3), 257–262. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Albert, M A.; Danielson, E.; Rifai, N.; Ridker, P M. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286 (1), 64–70. [PUBMED], [INFOTRIEVE], [CROSSREF]
  • Medical Expert Group Clinical algorithms on renal osteodystrophy. Nephrol. Dial. Transplant. 2000, 15 (Suppl 5), S39–S57.
  • Eknoyan, G.; Levin, A.; Levin, N W.; National Kidney Foundation K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003, 42 (Suppl 3), S1–S201.
  • Blacher, J.; Guerin, A P.; Pannier, B.; Marchais, S J.; London, G M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38 (4), 938–942. [PUBMED], [INFOTRIEVE]
  • Raggi, P.; Boulay, A.; Chasan-Taber, S.; Amin, N.; Dillon, M.; Burke, S K.; Chertow, G M. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?J. Am. Coll. Cardiol. 2002, 39 (4), 695–701. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Ganesh, S K.; Stack, A G.; Levin, N W.; Hulbert-Shearon, T.; Port, F K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. J. Am. Soc. Nephrol. 2001, 12 (10), 2131–2138. [PUBMED], [INFOTRIEVE], [CSA]
  • Chertow, G M.; Burke, S K.; Raggi, P.; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002, 62 (1), 245–252. [PUBMED], [INFOTRIEVE], [CROSSREF]
  • Nishizawa, Y.; Shoji, T.; Kakiya, R.; Tsujimoto, Y.; Tabata, T.; Ishimura, E.; Nakatani, T.; Miki, T.; Inaba, M. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int. 2003, 63 (Suppl 84), S117–S120. [CROSSREF]
  • Seliger, S L.; Weiss, N S.; Gillen, D L.; Kestenbaum, B.; Ball, A.; Sherrard, D J. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002, 61 (1), 297–304. [PUBMED], [INFOTRIEVE], [CROSSREF]
  • Ross, R. Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 1999, 340 (2), 115–126. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Zimmermann, J.; Herrlinger, S.; Pruy, A.; Metzger, T.; Wanner, C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999, 55 (2), 648–658. [PUBMED], [INFOTRIEVE], [CROSSREF]
  • Yeun, J Y.; Levine, R A.; Mantadilok, V.; Kaysen, G A. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2000, 35 (3), 469–476. [PUBMED], [INFOTRIEVE]
  • Ridker, P M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103 (13), 1813–1818. [PUBMED], [INFOTRIEVE]
  • Ichihara, A.; Hayashi, M.; Ryuzaki, M.; Handa, M.; Furukawa, T.; Saruta, T. Fluvastatin prevents development of arterial stiffness in hemodialysis patients with type 2 diabetes mellitus. Nephrol. Dial. Transplant. 2002, 17 (8), 1513–1517. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Vernaglione, L.; Cristofano, C.; Muscogiuri, P.; Chimienti, S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?Am. J. Kidney Dis. 2004, 43 (3), 471–478. [PUBMED], [INFOTRIEVE], [CROSSREF]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.